Milnacipran in provoked vestibulodynia

Efficacy and predictors of treatment success

Candace Brown, Gloria Bachmann, David Foster, Leslie Rawlinson, Jim Wan, Frank Ling

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: This study aimed to collect preliminary evidence on the efficacy of milnacipran in reducing pain in women with provoked vestibulodynia (PVD) and to identify which patient characteristics predict treatment success. Materials and Methods: A 12-week open-label trial was conducted in 22 women with PVD. The Pain Rating Index of the McGill Pain Questionnaire was the primary outcome measure. Other outcome measures included daily diaries, Beck Depression Inventory, State-Trait Anxiety Inventory, Female Sexual Function Index, Brief Pain Inventory, a personal or family history of fibromyalgia, and PVD subtype. Results: Milnacipran (50Y200 mg/d) significantly reduced pain severity on the Pain Rating Index (p = .001), coital pain (p = .001), tampon pain (p = .003), and mean vulvar pain (p e .001). Scores were also decreased on the Beck Depression Inventory (p = .015), State-Trait Anxiety Inventory (p = .046), and Brief Pain Inventory (p = .019) and increased on the Female Sexual Function Index (p = .004). Fibromyalgia history, PVD subtype, presence of depression or anxiety, and level of impairment did not affect treatment response. By logistic regression analysis, it was noted that the odds of treatment success was 3 times higher among women who, at pretreatment, had a sexually satisfying relationship compared to those who did not (odds ratio = 3.30, confidence interval = 1.04-10.50, p = .043). Conclusions: Milnacipran significantly reduced vestibular pain in women with PVD. Treatment success was predicted by pretreatment sexual satisfaction. A larger randomized controlled trial is necessary to confirm the efficacy of milnacipran in PVD and to identify other possible predictors of treatment outcome.

Original languageEnglish (US)
Pages (from-to)140-144
Number of pages5
JournalJournal of Lower Genital Tract Disease
Volume19
Issue number2
DOIs
StatePublished - Aug 1 2014

Fingerprint

Vulvodynia
Pain
Equipment and Supplies
Fibromyalgia
Anxiety
Depression
Outcome Assessment (Health Care)
milnacipran
Orgasm
compound A 12
Pain Measurement
Therapeutics

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Milnacipran in provoked vestibulodynia : Efficacy and predictors of treatment success. / Brown, Candace; Bachmann, Gloria; Foster, David; Rawlinson, Leslie; Wan, Jim; Ling, Frank.

In: Journal of Lower Genital Tract Disease, Vol. 19, No. 2, 01.08.2014, p. 140-144.

Research output: Contribution to journalArticle

Brown, Candace ; Bachmann, Gloria ; Foster, David ; Rawlinson, Leslie ; Wan, Jim ; Ling, Frank. / Milnacipran in provoked vestibulodynia : Efficacy and predictors of treatment success. In: Journal of Lower Genital Tract Disease. 2014 ; Vol. 19, No. 2. pp. 140-144.
@article{0440b2b584034d16bc4bd38ee5072c44,
title = "Milnacipran in provoked vestibulodynia: Efficacy and predictors of treatment success",
abstract = "Objective: This study aimed to collect preliminary evidence on the efficacy of milnacipran in reducing pain in women with provoked vestibulodynia (PVD) and to identify which patient characteristics predict treatment success. Materials and Methods: A 12-week open-label trial was conducted in 22 women with PVD. The Pain Rating Index of the McGill Pain Questionnaire was the primary outcome measure. Other outcome measures included daily diaries, Beck Depression Inventory, State-Trait Anxiety Inventory, Female Sexual Function Index, Brief Pain Inventory, a personal or family history of fibromyalgia, and PVD subtype. Results: Milnacipran (50Y200 mg/d) significantly reduced pain severity on the Pain Rating Index (p = .001), coital pain (p = .001), tampon pain (p = .003), and mean vulvar pain (p e .001). Scores were also decreased on the Beck Depression Inventory (p = .015), State-Trait Anxiety Inventory (p = .046), and Brief Pain Inventory (p = .019) and increased on the Female Sexual Function Index (p = .004). Fibromyalgia history, PVD subtype, presence of depression or anxiety, and level of impairment did not affect treatment response. By logistic regression analysis, it was noted that the odds of treatment success was 3 times higher among women who, at pretreatment, had a sexually satisfying relationship compared to those who did not (odds ratio = 3.30, confidence interval = 1.04-10.50, p = .043). Conclusions: Milnacipran significantly reduced vestibular pain in women with PVD. Treatment success was predicted by pretreatment sexual satisfaction. A larger randomized controlled trial is necessary to confirm the efficacy of milnacipran in PVD and to identify other possible predictors of treatment outcome.",
author = "Candace Brown and Gloria Bachmann and David Foster and Leslie Rawlinson and Jim Wan and Frank Ling",
year = "2014",
month = "8",
day = "1",
doi = "10.1097/LGT.0000000000000057",
language = "English (US)",
volume = "19",
pages = "140--144",
journal = "Journal of Lower Genital Tract Disease",
issn = "1089-2591",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Milnacipran in provoked vestibulodynia

T2 - Efficacy and predictors of treatment success

AU - Brown, Candace

AU - Bachmann, Gloria

AU - Foster, David

AU - Rawlinson, Leslie

AU - Wan, Jim

AU - Ling, Frank

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Objective: This study aimed to collect preliminary evidence on the efficacy of milnacipran in reducing pain in women with provoked vestibulodynia (PVD) and to identify which patient characteristics predict treatment success. Materials and Methods: A 12-week open-label trial was conducted in 22 women with PVD. The Pain Rating Index of the McGill Pain Questionnaire was the primary outcome measure. Other outcome measures included daily diaries, Beck Depression Inventory, State-Trait Anxiety Inventory, Female Sexual Function Index, Brief Pain Inventory, a personal or family history of fibromyalgia, and PVD subtype. Results: Milnacipran (50Y200 mg/d) significantly reduced pain severity on the Pain Rating Index (p = .001), coital pain (p = .001), tampon pain (p = .003), and mean vulvar pain (p e .001). Scores were also decreased on the Beck Depression Inventory (p = .015), State-Trait Anxiety Inventory (p = .046), and Brief Pain Inventory (p = .019) and increased on the Female Sexual Function Index (p = .004). Fibromyalgia history, PVD subtype, presence of depression or anxiety, and level of impairment did not affect treatment response. By logistic regression analysis, it was noted that the odds of treatment success was 3 times higher among women who, at pretreatment, had a sexually satisfying relationship compared to those who did not (odds ratio = 3.30, confidence interval = 1.04-10.50, p = .043). Conclusions: Milnacipran significantly reduced vestibular pain in women with PVD. Treatment success was predicted by pretreatment sexual satisfaction. A larger randomized controlled trial is necessary to confirm the efficacy of milnacipran in PVD and to identify other possible predictors of treatment outcome.

AB - Objective: This study aimed to collect preliminary evidence on the efficacy of milnacipran in reducing pain in women with provoked vestibulodynia (PVD) and to identify which patient characteristics predict treatment success. Materials and Methods: A 12-week open-label trial was conducted in 22 women with PVD. The Pain Rating Index of the McGill Pain Questionnaire was the primary outcome measure. Other outcome measures included daily diaries, Beck Depression Inventory, State-Trait Anxiety Inventory, Female Sexual Function Index, Brief Pain Inventory, a personal or family history of fibromyalgia, and PVD subtype. Results: Milnacipran (50Y200 mg/d) significantly reduced pain severity on the Pain Rating Index (p = .001), coital pain (p = .001), tampon pain (p = .003), and mean vulvar pain (p e .001). Scores were also decreased on the Beck Depression Inventory (p = .015), State-Trait Anxiety Inventory (p = .046), and Brief Pain Inventory (p = .019) and increased on the Female Sexual Function Index (p = .004). Fibromyalgia history, PVD subtype, presence of depression or anxiety, and level of impairment did not affect treatment response. By logistic regression analysis, it was noted that the odds of treatment success was 3 times higher among women who, at pretreatment, had a sexually satisfying relationship compared to those who did not (odds ratio = 3.30, confidence interval = 1.04-10.50, p = .043). Conclusions: Milnacipran significantly reduced vestibular pain in women with PVD. Treatment success was predicted by pretreatment sexual satisfaction. A larger randomized controlled trial is necessary to confirm the efficacy of milnacipran in PVD and to identify other possible predictors of treatment outcome.

UR - http://www.scopus.com/inward/record.url?scp=84905314689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905314689&partnerID=8YFLogxK

U2 - 10.1097/LGT.0000000000000057

DO - 10.1097/LGT.0000000000000057

M3 - Article

VL - 19

SP - 140

EP - 144

JO - Journal of Lower Genital Tract Disease

JF - Journal of Lower Genital Tract Disease

SN - 1089-2591

IS - 2

ER -